A Human Papillomavirus Vaccine
A recombinant quadrivalent human-papillomavirus-like particle vaccine, Gardasil (Merck), has been approved by the FDA for use in girls and women 9-26 years old to prevent diseases associated with infection with human papillomavirus (HPV) types 6, 11, 16, and 18, including genital warts, precancerous cervical, vaginal or vulvar lesions, and cervical cancer....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: A Human Papillomavirus Vaccine
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1241
Article Code: 1241a
Date: August 14, 2006
Volume: 48
Pages: 65-66
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1241
Article Code: 1241a
Date: August 14, 2006
Volume: 48
Pages: 65-66
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)